anti-delta CD20 immunotherapy (Etablissement Francais du Sang)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-delta CD20 immunotherapy (Etablissement Francais du Sang)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A